Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.80 Consensus Target Price from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $22.80.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald cut their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th.

Insider Activity

In related news, SVP Timothy J. Sangiovanni sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. This represents a 9.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Neil F. Mcfarlane sold 91,000 shares of Zevra Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the transaction, the chief executive officer owned 364,350 shares in the company, valued at $3,417,603. This trade represents a 19.98% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 114,158 shares of company stock worth $1,062,878. 2.40% of the stock is owned by company insiders.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZVRA. CWM LLC lifted its holdings in shares of Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after purchasing an additional 1,280 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC grew its position in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new position in Zevra Therapeutics during the second quarter valued at about $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $8.94 on Friday. The company has a market capitalization of $503.32 million, a PE ratio of 19.02 and a beta of 0.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62. The company’s 50 day moving average price is $8.68 and its 200 day moving average price is $9.40. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. The company had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. Research analysts expect that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.